每年出版 6 期
ISSN 打印: 1040-8401
ISSN 在线: 2162-6472
IF:
1.3
5-Year IF:
2.6
Eigenfactor:
0.00079
JCI:
0.24
SJR:
0.429
SNIP:
0.287
CiteScore™::
2.7
H-Index:
81
Indexed in
Gene Therapy for Rheumatoid Arthritis
Get access
摘要
With the aim of controlling disease relapse and bone deformation of individual joints, the application of gene therapy in rheumatoid arthritis (RA) has slowly progressed on a trial-and-error basis. Several new therapeutic targets have been identified in preclinical studies in animal models, although a limited number of gene-based clinical trials have been conducted. In this article, we summarize the status of gene therapy for RA by addressing issues related to innovating drug development. More disease- and target-specific preclinical tests are required to overcome the insufficient information regarding pharmacokinetics and toxicokinetics, which are related to safety issues in the field of RA gene therapy.
-
Liu Shuang, Lentiviral-Mediated Systemic RNA Interference In Vivo, in Rheumatoid Arthritis, 1868, 2018. Crossref
-
Liu Shuang, Mesenchymal Stem Cell Engineering, in Rheumatoid Arthritis, 1868, 2018. Crossref
-
Liu Shuang, Production of Lentiviral Particles, in Rheumatoid Arthritis, 1868, 2018. Crossref
-
Machaj Filip, Rosik Jakub, Szostak Bartosz, Pawlik Andrzej, The evolution in our understanding of the genetics of rheumatoid arthritis and the impact on novel drug discovery, Expert Opinion on Drug Discovery, 15, 1, 2020. Crossref
-
Wang Pingping, Li Ao, Yu Luodan, Chen Yu, Xu Di, Energy Conversion-Based Nanotherapy for Rheumatoid Arthritis Treatment, Frontiers in Bioengineering and Biotechnology, 8, 2020. Crossref
-
Li Yifan, Liang Qiangwei, Zhou Liyue, Liu Jinxia, Liu Yanhua, Metal nanoparticles: a platform integrating diagnosis and therapy for rheumatoid arthritis, Journal of Nanoparticle Research, 24, 4, 2022. Crossref